Vitrakvi 25 mg, Kapseln

7680672810010 CH-67281 Kapseln
Vitrakvi 25 mg, Kapseln
Vitrakvi 25 mg, Kapseln
Vitrakvi 25 mg, Kapseln
1 / 3
google

Article details

Package size
56
Selling units
56
Measure
Kapsel(n)
Galenic form
Kapseln
Galenic group
Tabletten

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
01/04/2026
Patient information leaflet
Français
01/04/2026
Patient information leaflet
Italien
01/04/2026
Summary of Product Characteristics
Allemand
01/04/2026
Summary of Product Characteristics
Français
01/04/2026
Summary of Product Characteristics
Italien
01/04/2026

Detailed composition

Substance Quantity Type Category
larotrectinibum
25.0 MG Substance Wirkstoff (Principe actif)
larotrectinibi sulfas
- Substance WIZUS
gelatina
- Substance HNIDK
E 171
- Substance FNIDK
lacca
- Substance HNIDK
E 132
- Substance FIMDK
E 171
- Substance FNIDK
propylenglycolum
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
dimeticonum 1000
- Substance HNIDK

Reimbursement information

Public price
CHF 1485.95
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/06/2022

Authorization holder

Bayer (Schweiz) AG

8045 Zürich

Authorization information

Swissmedic authorization number
67281
Drug name
Vitrakvi, Kapseln
Galenic form
KAPS
ATC Code
L01EX12
Authorization status
Z
Dispensing category
A
First authorization
28/05/2020
Authorization expiration date
19/02/2029
IT Number
07.16.1.
Domain
Human medicine
Field of application
Behandlung von soliden Tumoren mit NTRK (neurotrophe Tyrosin-Rezeptor-Kinase)-Genfusion

Package details

Description (FR)
VITRAKVI caps 25 mg bte 56 pce
Description (DE)
VITRAKVI Kaps 25 mg Ds 56 Stk
Market launch
28/05/2020
Narcotic (BTM)
No

Other package sizes (1)

VITRAKVI caps 100 mg bte 56 pce
56 KAP
GTIN: 7680672810027
View
Buy us a coffee Explore the data